1790089-97-2
Chemical Structure
LXRα agonist 1
- CAS No.: 1790089-97-2
- Formula:C28H27N3O2
- Molecular Weight:437.53
InChIKey: XNAXGNVKNMAHSV-UHFFFAOYSA-N
SMILES: O=C(C(C1=CC=CC=C1)=C2NC3=CC=C(N4CCCCC4)C=C3)N(CC5=CC=CC=C5)C2=O
Biological Activity: LXRα agonist 1 (Compound 40) is a selective LXRα agonist (EC50: 42 nM). LXRα agonist 1 also has a certain agonistic effect on LXRβ (EC50: 266 nM). LXRα agonist 1 promotes target gene transcription by stabilizing the ligand binding domain (LBD) of LXRα. LXRα agonist 1 exhibits potent antitumor effects in hepatocellular carcinoma cells when combined with the Raf inhibitor Sorafenib (HY-10201). LXRα agonist 1 can be used in the study of lipotoxic cancers[1].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LXRα agonist 1 | LXRα agonist 1 (Compound 40) is a selective LXRα agonist (EC50: 42 nM). LXRα agonist 1 also has a certain agonistic effect on LXRβ (EC50: 266 nM). LXRα agonist 1 promotes target gene transcription by stabilizing the ligand binding domain (LBD) of LXRα. LXRα agonist 1 exhibits potent antitumor effects in hepatocellular carcinoma cells when combined with the Raf inhibitor Sorafenib (HY-10201). LXRα agonist 1 can be used in the study of lipotoxic cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
